Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches.


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 11 5 2019
medline: 18 12 2019
entrez: 11 5 2019
Statut: ppublish

Résumé

Salvage radical prostatectomy has historically yielded a poor functional outcome and a high complication rate. However, recent reports of robotic salvage radical prostatectomy have demonstrated improved results. In this study we assessed salvage radical prostatectomy functional outcomes and complications when comparing robotic and open approaches. We retrospectively collected data on salvage radical prostatectomy for recurrent prostate cancer after local nonsurgical treatment at 18 tertiary referral centers from 2000 to 2016. The Clavien-Dindo classification was applied to classify complications. Complications and functional outcomes were evaluated by univariable and multivariable analysis. We included 395 salvage radical prostatectomies, of which 186 were open and 209 were robotic. Robotic salvage radical prostatectomy yielded lower blood loss and a shorter hospital stay (each p <0.0001). No significant difference emerged in the incidence of major and overall complications (10.1%, p=0.16, and 34.9%, p=0.67), including an overall low risk of rectal injury and fistula (1.58% and 2.02%, respectively). However, anastomotic stricture was more frequent for open salvage radical prostatectomy (16.57% vs 7.66%, p <0.01). Overall 24.6% of patients had had severe incontinence, defined as 3 or more pads per day, for 12 or 6 months. On multivariable analysis robotic salvage radical prostatectomy was an independent predictor of continence preservation (OR 0.411, 95% CI 0.232-0.727, p=0.022). Limitations include the retrospective nature of the study and the absence of a standardized surgical technique. In this contemporary series to our knowledge salvage radical prostatectomy showed a low risk of major complications and better functional outcomes than previously reported. Robotic salvage radical prostatectomy may reduce anastomotic stricture, blood loss and hospital stay, and improve continence outcomes.

Identifiants

pubmed: 31075058
doi: 10.1097/JU.0000000000000327
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Comparative Study Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

725-731

Investigateurs

Georgio Calleris (G)
Stefania Munegato (S)
Anna Palazzetti (A)
Francesca Pisano (F)
Umberto Ricardi (U)
Antonio Battaglia (A)
Roland van Velthoven (R)
Paul Cathcart (P)
Salvatore Smelzo (S)
Joseph Smith (J)
Andre Abreu (A)
Inderbir S. Gill (IS)

Auteurs

Paolo Gontero (P)

Department of Urology, San Giovanni Battista Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Giancarlo Marra (G)

Department of Urology, San Giovanni Battista Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Paolo Alessio (P)

Department of Urology, San Giovanni Battista Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Claudia Filippini (C)

Department of Statistics, University of Turin, Turin, Italy.

Marco Oderda (M)

Department of Urology, San Giovanni Battista Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Fernando Munoz (F)

Department of Radiotherapy, Parini Hospital, Aosta, Italy.

Estefania Linares (E)

Department of Urology, Institut Mutualiste Montsouris, F-75013 Paris, France.

Rafael Sanchez-Salas (R)

Department of Urology, Institut Mutualiste Montsouris, F-75013 Paris, France.

Ben Challacombe (B)

Urology 47 Centre, Guy's Hospital, London, United Kingdom.

Prokar Dasgupta (P)

Urology 47 Centre, Guy's Hospital, London, United Kingdom.
King's College London, London, United Kingdom.

Sanchia Goonewardene (S)

Urology 47 Centre, Guy's Hospital, London, United Kingdom.

Rick Popert (R)

Urology 47 Centre, Guy's Hospital, London, United Kingdom.

Declan Cahill (D)

Royal Marsden Hospital, London, United Kingdom.

David Gillatt (D)

Bristol NHS Foundation Trust, Bristol, United Kingdom.

Raj Persad (R)

Bristol NHS Foundation Trust, Bristol, United Kingdom.

Juan Palou (J)

Fundaciò Puigvert, Barcelona, Spain.

Steven Joniau (S)

Leuven University Hospitals, Leuven, Belgium.

Thierry Piechaud (T)

Clinique Saint Augustin, Bordeaux, France.

Alessandro Morlacco (A)

Mayo Clinic, Rochester, Minnesota.

Sharma Vidit (S)

Mayo Clinic, Rochester, Minnesota.

Morgan Rouprêt (M)

Sorbonne Université, GRC No. 5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France.

Alexandre De La Taille (A)

CHU Mondor, Créteil, France.

Simone Albisinni (S)

Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium.

Giorgio Gandaglia (G)

OLV Hospital, Aalst, Belgium.

Alexander Mottrie (A)

OLV Hospital, Aalst, Belgium.

Shreyas Joshi (S)

Vanderbilt University, Medical Center North, Nashville, Tennessee.

Gabriel Fiscus (G)

Vanderbilt University, Medical Center North, Nashville, Tennessee.

Andre Berger (A)

USC Norris Comprehensive Cancer Center and Hospital, University of Southern California, California.

Monish Aron (M)

USC Norris Comprehensive Cancer Center and Hospital, University of Southern California, California.

Henk Van Der Poel (H)

Netherlands Cancer Institute, Amsterdam, Netherlands.

Derya Tilki (D)

Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Nathan Lawrentschuk (N)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne and Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.

Declan G Murphy (DG)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne and Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.

Gordon Leung (G)

Division of Surgery, Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas.

John Davis (J)

Division of Surgery, Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Robert Jeffrey Karnes (RJ)

Department of Oncology, University of Turin, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH